China-based GluBio Pharmaceutical has received a USD 30 million strategic equity investment from Sanofi to advance the development of two of its core molecular glue degrader programs, GLB-005 and GLB-007. As part of the agreement, Sanofi has acquired newly issued preferred shares and has been granted a right of first negotiation (ROFN) for an exclusive license to develop and commercialise the two clinical-stage assets. Both candidates are currently in preclinical development, with Phase I studies potentially commencing as early as late 2026.

The two programs are designed to degrade proteins that suppress foetal haemoglobin, with the aim of reactivating its expression to provide a novel oral disease-modifying therapy for patients with sickle cell disease. Founded in 2021, GluBio focuses on discovering and developing molecular glue degraders for genetic disorders, oncology and autoimmune diseases. The company utilises its proprietary Glue Degrader Discovery (GDD) platform and already has two other molecular glue candidates, GLB-001 and GLB-002, in Phase I trials.

PharmCube's NextBiopharm® database shows that GluBio's pipeline covers the fields of oncology and immunology. Click here to request a free trial for NextBiopharm®.